Biotech Values

[genisi]

Obviously, Neugranin [from CoGenesys], which is albumin based, will be non-infringing.

I don't think so. CoGenesys's albumin fusion technology makes Neugranin a long-acting form of G-CSF (by increasing its bio-availability and half life), but it would still infringe Amgen's 5,580,755 and 5,582,823 patents (running until Dec. 2013), because the first covers all sequences coding for amino acid residues of hpG-CSF (the native as well as its analogs) and the other covers methods for treating patients with these protein sequences. I believe that is why Teva settled.